GAD-7 Score
Generalised Anxiety Disorder 7-item scale — a validated self-report questionnaire for screening and monitoring anxiety severity. Scores range from 0 to 21, mapping to four severity categories, with established thresholds for clinical action. Also useful as a brief screen for panic disorder, social anxiety disorder, and post-traumatic stress disorder.
Calculate GAD-7 Score
For each of the seven items, select the response that best describes how often the patient has been bothered by the problem over the past two weeks. The tool also includes the optional functional impairment question, which does not contribute to the total score but provides important clinical context.
The GAD-7 is a screening and severity monitoring tool, not a diagnostic instrument. A positive screen suggests the need for a clinical evaluation to confirm the diagnosis, identify the specific anxiety disorder, exclude medical causes, and assess for comorbid conditions (particularly depression — consider co-administering the PHQ-9).
Understanding the GAD-7
The Generalised Anxiety Disorder 7-item (GAD-7) scale was developed by Drs Robert Spitzer, Kurt Kroenke, Janet Williams, and Bernd Löwe, and published in 2006. It was designed as a companion tool to the PHQ-9 for use in primary care settings, where anxiety disorders are prevalent but frequently under-recognised. Together, the PHQ-9 and GAD-7 provide a brief, validated assessment of the two most common categories of mental health conditions in primary care.
The seven items were drawn from the DSM-IV criteria for generalised anxiety disorder and refined through factor analysis in a large primary care sample. Although designed specifically for GAD, subsequent validation has demonstrated that the GAD-7 also performs well as a screener for other anxiety disorders, including panic disorder, social anxiety disorder, and post-traumatic stress disorder — making it a useful transdiagnostic anxiety measure in clinical practice.
Scoring Method
Each of the 7 items is scored 0–3:
0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
Total score range: 0–21
The recall period is the past two weeks. The questionnaire can be self-administered or clinician-administered and typically takes under 3 minutes to complete.
Diagnostic Performance
For GAD at a cutoff of ≥10:
Sensitivity: 89%
Specificity: 82%
For any anxiety disorder at a cutoff of ≥10, sensitivity ranges from 68–89% and specificity from 82–88% depending on the specific disorder. The GAD-7 has the strongest operating characteristics for generalised anxiety disorder and somewhat lower sensitivity for specific phobias and OCD.
The GAD-7 measures anxiety symptom severity, not a specific diagnosis. A high score indicates a significant burden of anxiety symptoms — but those symptoms may arise from generalised anxiety disorder, panic disorder, social anxiety, PTSD, mixed anxiety and depression, a medical condition, substance use, or a combination of these. The score tells you how anxious the patient is, not why.
Score Interpretation & Treatment Thresholds
The GAD-7 severity categories were established in the original validation study by Spitzer and colleagues (2006). Each threshold was associated with distinct levels of functional impairment, disability days, physician visits, and symptom-related difficulty.
| Score | Severity | Proposed Treatment Action |
|---|---|---|
| 0–4 | Minimal anxiety | No treatment specifically indicated for anxiety. Re-screen if symptoms recur or clinical suspicion persists. A low score in a patient already on treatment may indicate treatment response or remission. |
| 5–9 | Mild anxiety | Watchful waiting with repeat GAD-7 at follow-up. Consider psychoeducation, self-help resources, relaxation techniques, and lifestyle modifications (exercise, caffeine reduction, sleep hygiene). Initiate treatment if symptoms are persistent, functionally impairing, or comorbid with depression. |
| 10–14 | Moderate anxiety | Treatment is recommended. Options include pharmacotherapy (SSRIs or SNRIs as first-line), evidence-based psychotherapy (CBT is the strongest evidence base for anxiety disorders), or a combination. Patient preference should guide choice. Plan repeat GAD-7 to monitor response. |
| 15–21 | Severe anxiety | Active treatment is strongly recommended. Initiate pharmacotherapy and/or psychotherapy. Assess for comorbid depression (administer PHQ-9), substance use, and suicidal ideation. Consider psychiatric referral if symptoms are severe, complex, treatment-resistant, or if the patient is significantly functionally impaired. Close monitoring is essential. |
A GAD-7 score of ≥10 is the most widely used threshold for identifying clinically significant anxiety warranting treatment, and corresponds to a point where functional impairment becomes increasingly likely. However, do not ignore a score of 5–9 in a patient with significant functional impairment or comorbid depression — the functional impairment question and PHQ-9 provide essential additional context for treatment decisions.
Monitoring Treatment Response
Like the PHQ-9, the GAD-7 is validated for repeated use to monitor symptom trajectory. A reduction of ≥50% from baseline suggests treatment response; a final score of <5 suggests remission. A change of ≥4 points is considered the minimum clinically important difference. Monitor at 4–6 week intervals during active treatment, extending to longer intervals during maintenance.
Clinical Use & Differential Considerations
The GAD-7 is widely used as a universal anxiety screener, but understanding its strengths and limitations across different anxiety diagnoses — and knowing when to use complementary tools — is essential for effective clinical use.
Although the GAD-7 was developed for generalised anxiety disorder, its items capture symptoms common across multiple anxiety disorders — nervousness, uncontrollable worry, restlessness, irritability, and a sense of dread. This makes it a useful “front door” screener for anxiety in primary care. At a cutoff of ≥10, the GAD-7 has reasonable sensitivity for several anxiety diagnoses:
- Generalised anxiety disorder: sensitivity 89%, specificity 82% (the intended use)
- Panic disorder: sensitivity 74%, specificity 81%
- Social anxiety disorder: sensitivity 72%, specificity 80%
- Post-traumatic stress disorder: sensitivity 66%, specificity 81%
However, the GAD-7 is less sensitive for specific phobias and obsessive-compulsive disorder, which have more circumscribed symptom profiles that may not elevate the general anxiety items. When a specific anxiety disorder is suspected, a disorder-specific tool should be used for definitive screening (e.g. PCL-5 for PTSD, SPIN for social anxiety).
The GAD-2 consists of the first two GAD-7 items — “feeling nervous, anxious, or on edge” and “not being able to stop or control worrying” — scored identically (0–3 each, total 0–6). At a cutoff of ≥3, the GAD-2 has a sensitivity of 86% and specificity of 83% for generalised anxiety disorder.
Like the PHQ-2, the GAD-2 can serve as a rapid first-stage screener. If the GAD-2 score is ≥3, proceed to the full GAD-7 for severity grading and monitoring. The GAD-2 is a practical choice for universal screening in high-volume settings where administering the full seven items to every patient is not feasible.
Anxiety and depression co-occur in approximately 50–60% of patients with either condition. This comorbidity is associated with greater symptom severity, worse functional impairment, poorer treatment outcomes, and increased suicidality. Administering the GAD-7 and PHQ-9 together takes under 5 minutes and provides a comprehensive picture of the two most common mental health conditions in primary care.
When both scores are elevated (≥10 on each), treatment should address both conditions. SSRIs and SNRIs are effective for both anxiety and depression, making them logical first-choice pharmacotherapy when both are present. CBT protocols exist that target comorbid anxiety and depression simultaneously. Prioritise the more severe or functionally impairing condition for initial treatment focus while monitoring both trajectories.
Note that some GAD-7 items (restlessness, irritability, difficulty concentrating) overlap with depressive symptoms, which can inflate the GAD-7 in patients with primary depression and vice versa. Always interpret both scores together rather than in isolation.
An elevated GAD-7 score should prompt consideration of medical causes of anxiety before attributing symptoms solely to a primary anxiety disorder. The GAD-7 will detect anxiety symptoms regardless of their aetiology. Conditions that may present with prominent anxiety include:
- Endocrine: hyperthyroidism, phaeochromocytoma, Cushing syndrome, hypoglycaemia, hyperparathyroidism
- Cardiac: arrhythmias, mitral valve prolapse, heart failure, angina
- Respiratory: asthma, COPD exacerbation, pulmonary embolism
- Neurological: seizure disorders (inter-ictal anxiety), vestibular disorders, multiple sclerosis
- Substance-related: caffeine excess, stimulant use, alcohol/benzodiazepine withdrawal, cannabis (paradoxical anxiety), corticosteroid therapy
- Medication side effects: bronchodilators, thyroid supplements, decongestants, certain SSRIs (initial activation), stimulants
A basic workup in patients with new-onset anxiety or atypical features should include thyroid function tests, basic metabolic panel, and a careful medication/substance history. Consider further investigations based on clinical presentation.
Several validated anxiety instruments are available. The choice depends on the clinical context and the specific question being asked:
- GAD-7: 7 items, self-report, free. Best for general anxiety screening and monitoring in primary care. Transdiagnostic utility. Pairs naturally with PHQ-9.
- Hamilton Anxiety Rating Scale (HAM-A): 14 items, clinician-rated. Reference standard in clinical trials. Requires training. Distinguishes psychic from somatic anxiety symptoms.
- Beck Anxiety Inventory (BAI): 21 items, self-report, copyrighted. Emphasises somatic symptoms of anxiety and panic. May be less sensitive for cognitive/worry-based presentations of GAD.
- State-Trait Anxiety Inventory (STAI): 40 items, self-report, copyrighted. Separates situational (state) from enduring (trait) anxiety. Widely used in research but less practical for clinical screening.
- PROMIS Anxiety Short Form: 4–8 items, free, part of the NIH PROMIS system. Calibrated using item response theory. Useful for cross-disorder comparison.
The GAD-7’s combination of brevity, free availability, dimensional scoring, dual screening-and-monitoring utility, and extensive validation across languages and settings makes it the preferred first-line anxiety screening tool in most clinical guidelines.
Administer the GAD-7 and PHQ-9 together routinely — it takes under 5 minutes and screens for both of the conditions responsible for the majority of mental health morbidity in primary care. Interpret the two scores in tandem: overlapping high scores suggest comorbid anxiety and depression, which changes both the treatment approach and the prognosis.
Special Populations & Considerations
Cross-cultural considerations: The GAD-7 has been translated and validated in over 20 languages. However, the conceptualisation and expression of anxiety varies across cultures — some populations emphasise somatic manifestations of distress (headaches, chest tightness, gastrointestinal symptoms) rather than cognitive worry. Validated translations should be used where available, and scores should be interpreted with cultural context in mind.
Common Pitfalls & Limitations
The GAD-7 measures the severity of anxiety symptoms over the past two weeks — it does not establish a DSM-5 diagnosis of generalised anxiety disorder. GAD requires excessive worry about multiple domains, present more days than not for at least six months, associated with at least three of six somatic/cognitive symptoms, and causing significant functional impairment. A single elevated GAD-7 score captures a two-week snapshot, not the six-month pattern required for diagnosis.
Furthermore, a high GAD-7 score may reflect panic disorder, social anxiety, PTSD, adjustment disorder, anxiety secondary to a medical condition, or substance-related anxiety — not GAD. Always follow a positive screen with a diagnostic clinical interview to establish the specific disorder and its chronicity.
Anxiety and depression co-occur in approximately half of all cases. Screening with the GAD-7 alone risks missing comorbid depression, which substantially worsens prognosis and changes treatment approach. The same is true in reverse — using only the PHQ-9 without the GAD-7 may miss comorbid anxiety.
Best practice is to administer both tools together. The combined PHQ-9 + GAD-7 takes under 5 minutes and provides a comprehensive assessment of the two most common mental health conditions in primary care. Many electronic health record systems now include both tools as a standard screening pair.
A significant pitfall is attributing a high GAD-7 score to a primary anxiety disorder without considering medical mimics. Hyperthyroidism, phaeochromocytoma, cardiac arrhythmias, stimulant/caffeine use, and medication side effects can all produce anxiety symptoms that will elevate the GAD-7 score.
For any patient presenting with new-onset anxiety, particularly if it is severe, atypical in presentation, or unresponsive to standard treatment, a minimum medical workup should include: thyroid function tests (TSH), basic metabolic panel, and a thorough review of medications and substance use (especially caffeine, stimulants, corticosteroids, bronchodilators, and recent initiation or discontinuation of psychotropic medications).
A common clinical response to a high GAD-7 score is to prescribe a benzodiazepine for symptom relief. While benzodiazepines are effective anxiolytics in the short term, they carry significant risks: tolerance, dependence, withdrawal, cognitive impairment (particularly in the elderly), falls risk, and potential interaction with alcohol and opioids. Guidelines from NICE, APA, and others consistently recommend SSRIs or SNRIs as first-line pharmacotherapy for generalised anxiety disorder, with CBT as an equally effective first-line treatment.
Benzodiazepines may be appropriate for brief, time-limited use while waiting for SSRI/SNRI onset of action (typically 2–4 weeks), but a plan for discontinuation should be established at the outset. They should generally be avoided in patients with substance use disorders, the elderly, and those with respiratory compromise.
The standard treatment threshold of ≥10 is a population-level guideline, not an absolute clinical rule. A patient with a GAD-7 score of 7 (mild) who reports “extremely difficult” functional impairment, avoidance behaviour, or inability to work may need treatment just as much as a patient scoring 12 with preserved function.
The functional impairment question is a crucial adjunct to the total score. Additionally, patients with comorbid depression (elevated PHQ-9), substance use, chronic medical conditions, or a history of prior anxiety episodes may warrant treatment at lower GAD-7 thresholds. Clinical judgement should integrate the score, functional impact, patient preference, and comorbidity profile.
Quick Reference Summary
| Score Range | Severity | Action |
|---|---|---|
| 0–4 | Minimal | Routine re-screening |
| 5–9 | Mild | Watchful waiting, lifestyle, psychoeducation |
| 10–14 | Moderate | Treatment recommended (SSRI/SNRI or CBT) |
| 15–21 | Severe | Active treatment; assess comorbidity; consider referral |
The Golden Rule: Always pair the GAD-7 with the PHQ-9. Anxiety and depression are the “bread and butter” of primary care mental health — screening for one without the other is like checking the blood pressure without checking the pulse. The two scores together take less than 5 minutes and transform the clinical conversation.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. DOI: 10.1001/archinte.166.10.1092
- Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–325. DOI: 10.7326/0003-4819-146-5-200703060-00004
- Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–274. DOI: 10.1097/MLR.0b013e318160d093
- Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. DOI: 10.1016/j.genhosppsych.2015.11.005
- Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. DOI: 10.1046/j.1525-1497.2001.016009606.x
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107. DOI: 10.31887/DCNS.2017.19.2/bbandelow
- National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. NICE guideline CG113. Updated 2020. Available at: nice.org.uk/guidance/cg113
- Toussaint A, Hüsing P, Gumz A, et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020;265:395–401. DOI: 10.1016/j.jad.2020.01.032
- Mossman SA, Luft MJ, Schroeder HK, et al. The Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder: signal detection and validation. Ann Clin Psychiatry. 2017;29(4):227–234. PMID: 29069107
- Simpson W, Glazer M, Michalski N, Steiner M, Frey BN. Comparative efficacy of the Generalized Anxiety Disorder 7-item scale and the Edinburgh Postnatal Depression Scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period. Can J Psychiatry. 2014;59(8):434–440. DOI: 10.1177/070674371405900806